Avant Brands Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Avant Brands's earnings have been declining at an average annual rate of -0.7%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 41% per year.
Anahtar bilgiler
-0.7%
Kazanç büyüme oranı
21.5%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 7.3% |
| Gelir büyüme oranı | 41.0% |
| Özkaynak getirisi | -32.8% |
| Net Marj | -51.0% |
| Son Kazanç Güncellemesi | 31 Aug 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Avant Brands nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Aug 24 | 30 | -15 | 12 | 0 |
| 31 May 24 | 28 | -11 | 12 | 0 |
| 29 Feb 24 | 27 | -8 | 11 | 0 |
| 30 Nov 23 | 26 | -5 | 12 | 0 |
| 31 Aug 23 | 29 | -4 | 11 | 0 |
| 31 May 23 | 27 | -3 | 9 | 0 |
| 28 Feb 23 | 23 | -7 | 12 | 0 |
| 30 Nov 22 | 20 | -8 | 11 | 0 |
| 31 Aug 22 | 15 | -10 | 11 | 0 |
| 31 May 22 | 13 | -14 | 10 | 0 |
| 28 Feb 22 | 12 | -12 | 7 | 0 |
| 30 Nov 21 | 9 | -11 | 6 | 0 |
| 31 Aug 21 | 9 | -11 | 5 | 0 |
| 31 May 21 | 9 | -9 | 5 | 0 |
| 28 Feb 21 | 8 | -8 | 5 | 0 |
| 30 Nov 20 | 8 | -10 | 5 | 0 |
| 31 Aug 20 | 7 | -4 | 5 | 0 |
| 31 May 20 | 6 | -6 | 6 | 0 |
| 29 Feb 20 | 5 | -8 | 7 | 0 |
| 30 Nov 19 | 2 | -10 | 9 | 0 |
| 31 Aug 19 | 1 | -11 | 10 | 0 |
| 31 May 19 | 0 | -11 | 11 | 0 |
| 28 Feb 19 | 0 | -10 | 10 | 0 |
| 30 Nov 18 | 0 | -11 | 10 | 0 |
Kaliteli Kazançlar: 1BU is currently unprofitable.
Büyüyen Kar Marjı: 1BU is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 1BU is unprofitable, and losses have increased over the past 5 years at a rate of 0.7% per year.
Büyüme Hızlandırma: Unable to compare 1BU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: 1BU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Özkaynak Getirisi
Yüksek ROE: 1BU has a negative Return on Equity (-32.84%), as it is currently unprofitable.